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Abstract 
Current in vivo and in vitro models fail to accurately recapitulate the human heart microenvironment for biomedical 
applications. This study explores the use of cardiac spheroids (CSs) to biofabricate advanced in vitro models of the human 
heart. CSs were created from human cardiac myocytes, fibroblasts and endothelial cells, mixed within optimal alginate/gelatin 
hydrogels and then bioprinted on a microelectrode plate for drug testing. Bioprinted CSs maintained their structure and viability 
for at least 30 days after printing. Vascular endothelial growth factor (VEGF) promoted endothelial cell branching from CSs 
within hydrogels. Alginate/gelatin-based hydrogels enabled spheroids fusion, which was further facilitated by addition of 
VEGF. Bioprinted CSs contracted spontaneously and under stimulation, allowing to record contractile and electrical signals 
on the microelectrode plates for industrial applications. Taken together, our findings indicate that bioprinted CSs can be used 
to biofabricate human heart tissues for long term in vitro testing. This has the potential to be used to study biochemical, 
physiological and pharmacological features of human heart tissue. 
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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of 
morbidity and death in the modern world.[1-4] More 
physiological models to study the human heart 
microenvironment may advance how to detect, prevent and 
treat CVD in the future.[5] In this context, in vitro testing 
represents an essential part of developing treatment as well as 
understanding underlying mechanisms of CVD. [5, 6] These 
include in vitro cardiac models utilizing human cells to test 
their molecular, cellular and extracellular response when they 
are exposed to pathophysiological conditions, currently 
limited by their ability to replicate the complex cardiac tissue 
environment.[1, 5, 7] Advanced bioengineered cardiac in vitro 
models can assist in improving current treatments by better 
replicating the cardiac tissue microenvironment under 
physiological and pathological conditions..[5] Current in vitro 
models which utilize monolayer cell cultures are limited by 
cells growing as a monolayer on a flat surface contrary to the 
three-dimensional nature of tissue. Three-dimensional (3D) 
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cultures, on the other hand, better mimic the cell structure and 
microenvironment found in vivo and provide advanced tools 
to improve accuracy of in vitro testing.[5] These cultures also 
improve the viability and function of cardiac cells expanding 
the potential for diagnostic and therapeutic applications.[8] 
Among several 3D cultures of cardiac cells, cardiac cell 
aggregates (known as “ cardiac spheroids” or CSs) are used in 
multiple applications, including in vitro testing. [5, 7, 9] More 
recently, spheroid cultures have been employed together with 
3D bioprinting technology to create in vitro 3D models of 
tissue and organs.[10] In this approach, a bioprinter deposits the 
biological ink (or “bioink”) layer-by-layer to create a three-
dimensional structure. In this manuscript, the bioink is 
composed of cardiac spheroid cultures embedded within 
tissue-specific permissive hydrogels for optimal cardiac cell 
viability and function. Bioprinting technology has been 
explored as a method to generate and use spheroids to allow 
for scalable, uniform and automated biofabrication of 
tissues.[11, 12]  The potential use of bioinks composed of 
spheroids and hydrogels as building blocks for tissue 
engineering purposes have been previously explored.[13, 14] 
Spheroid extrusion through a micropipette nozzle occurs after 
spheroid generation, either by extruding spheroids alone or by 
embedding them within supporting hydrogels. Spheroid 
fusion can occur in hanging drop cultures by reducing surface 
tension and by promoting cell-cell adhesion.[13]  During this 
process, the application of vascular endothelial growth factor 
(VEGF) plays a major role in promoting spheroid fusion 
within hydrogels.[13] Similarly, fusion of spheroids presenting 
a vascular network within hydrogels with specific viscosity is 
feasible.[13] 
One of the most challenging tasks for the optimal 
bioengineering of viable and functional cardiac tissues is the 
recreation of its vascularization.[1, 15] As most organs and 
tissues in our body are fully perfused with blood, a fully 
vascularized 3D in vitro model will more accurately replicate 
the biochemical, morphological and physiological behavior of 
cells compared to existing in vitro models.[16-18] More recently, 
biofabrication of personalized cardiac tissues by 3D 
bioprinting of patient-derived stem cells has been explored for 
in vivo applications, including myocardial regeneration in 
heart failure patients to replace damaged heart tissues.[10, 19, 20] 
However, these approaches failed at fully generating 
functional tissues that completely recapitulate biochemical, 
morphological and physiological features typical of the in vivo 
heart, including a proper vascular network formation and 
contractile function. The objective of this study was the 
identification of optimal hydrogels using alginate and gelatin 
with viscoelastic properties that are similar to the ones of 
native cardiac tissue, while allowing cells to survive and 
function properly within the biofabricated tissue. This study 
presents a way forward in the field of cardiac bioengineering 
by developing an approach that better replicates the human 
heart microenvironment by bioprinting cardiac spheroids in 
hydrogels.[16, 21] The hypothesis is that cardiac spheroids can 
be used as building blocks to 3D bioprint in vitro models of 
the human heart within optimal alginate-based hydrogels. The 
goal of the present work was to evaluate different hydrogel 
combinations for bioprinting human cardiac spheroids and 
their utility for assessment of functional properties, with the 
potential use for testing in vitro of cardiac cell viability and 
function. 
2. Material and Methods 
2.1 Bioprinting 
All bioprinting was carried out using either a custom-made 
extrusion based bioprinter from REGEMAT 3D, (Spain) or a 
CELLINK BioX (Sweden). The REGEMAT3D bioprinter 
was kept within a Biosafety Cabinet (BSC) and it was 
programmed through G-codes (Figure S1). The bioprinting 
procedure is captured in Video 1. The BioX bioprinter is a 
standalone system that allows a sterile environment without 
having to move the device to a BSC. 
2.2 Hydrogel Formation and Crosslinking 
Hydrogels were made by dissolving dry powders up to 30 
minutes or until completely dissolved in Dulbecco’s Modified 
Eagle’s Medium – high glucose (Life Science, Sigma Aldrich) 
with 1% (v/v) Penicillin-Streptomycin (50 units/ml penicillin 
and 50 µg streptomycin/mL) and 1% (v/v) 200 mM L-
Glutamine. Powders used were alginic acid sodium salt from 
brown algae (Al) and gelatin from bovine skin (Ge). The 
media was heated to 50°C, the gelatin and alginate powders 
were then slowly added and completely dissolved with 
stirring. The resulting hydrogels were divided into 15 mL 
aliquots and stored at 4°C. 
Different hydrogel compositions were tested including: i) 2% 
(w/v) Al and 6 % (w/v) Ge, ii) 3% (w/v) Al and (w/v) 6% Ge, 
iii) 4% (w/v) Al and 8% (w/v) Ge. The hydrogel was 
crosslinked with a sterile 0.2 μm filtered calcium chloride 
solution made from 2% (w/v) calcium chloride dihydrate 
powder in Dulbecco’s Phosphate Buffered Saline (DPBS) 
with no Calcium Chloride or Magnesium Chloride (Gibco, 
ThermoFisher Scientific) and 50 ml aliquots were stored at 
4°C with the lid fully sealed with parafilm to prevent any 
potential evaporation. Once bioprinted, hydrogels first were 
crosslinked and then incubated at 37°C with culture media in 
presence or absence of spheroids. 
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2.3 Mechanical Testing of Hydrogels Using Unconfined 
Compression Test 
The Young’s modulus of hydrogel samples (n = 3) was 
measured through unconfined compression on a TA 
Instruments Dynamic Hybrid Rheometer (DHR-3, TA 
Instruments). An 8mm diameter punch biopsy was taken from 
each hydrogel and placed between the top and bottom 
geometries. Mechanical characterisation of the hydrogels was 
performed using unconfined compression analysis, with a 
constant compression rate of 10mm/min with data output in 
the form of axial force (N) and gap (mm). During the 
measurements, the axial force was changed from 0 N to 0.2 N. 
Results were analysed and a stress/strain curve for each 
replicate hydrogel was obtained. The Young’s modulus (kPa) 
was obtained from the linear region of the stress/strain curve. 
All samples were measured at 25° C and on the same day. 
2.4 Micromechanical Testing of Hydrogels Using Brillouin 
Microspectroscopy 
Brillouin microspectroscopy was used to determine 
viscoelastic properties of all types of hydrogel materials. The 
Brillouin microspectroscopy system consisted of a continuous 
wave 660 nm Laser (Torus, Laser Quantum), a confocal 
microscope (CM1, JRS Instruments) and a scanning tandem 
Fabry-Perot interferometer (TFP1, JRS Instruments). The 
laser power on the sample was 50 mW, and the acquisition 
time per point was 1-10 s. The raw spectra, containing 
Rayleigh and Brillouin peaks, were fitted using the Damped 
Harmonic Oscillator model, and the position of the Stokes and 
anti-Stokes Brillouin peaks were determined with uncertainty 
below 10 MHz. Each gel composition was tested 12 times (4 
sample repeats with 3 measurements per each sample) and the 
average and standard deviation in the Brillouin frequency shift 
(Ω) across the measurement set were determined. To avoid the 
effects of dehydration on gel viscoelasticity, the samples were 
kept in the incubator prior to the measurements at constant 
temperature and humidity. [22] 
2.5 Pore Size Measurements in Bioprinted Hydrogels using 
Scanning Electron Microscopy (SEM) 
In order to characterize the pore structure of bioprinted 
hydrogels, scanning electron microscopy (SEM) was 
employed. Briefly, hydrogels were first dried in a vacuum 
oven (100kPa) for 24 hours, then coated with platinum using 
a K575x Sputter coater (Emitech Quorum), and finally imaged 
using a S-3400 SEM system (Hitachi). Pore size was measured 
using at least eight random areas from each sample (two per 
day point) using ImageJ software (NIH, Bethesda) as 
previously described. [23] 
2.6 Cell Culture and Spheroid Formation 
Different cells were cultured and used: i) adult human cardiac 
fibroblasts (hCFs) which were cultured in DMEM with 1% 
(v/v) Penicillin-Streptomycin (50 units/mL penicillin and 50 
µg streptomycin/mL), 1% (v/v) 200 mM L-Glutamine and 
10% (v/v) Fetal Bovine Serum (FBS); ii) adult human 
coronary artery endothelial cells (HCAEC) which were 
cultured in MesoEndo Cell Growth Medium (Cell 
Applications, Inc); and iii) Cor.4U SC-derived cardiac 
myocytes, which were cultured in Cor.4U media according to 
manufacturer’s instructions (Ncardia). 
Spheroids were formed using a 384-hanging drop culture plate 
(Perfecta3D, 3D Biomatrix, Inc.) as previously described.[9, 22] 
Based on previous studies, human spheroids were formed by 
co-culturing 5,000 fibroblasts, 5,000 endothelial cells and 
10,000 myocytes at a ratio of 1:1:2.[9, 22]  A 20 μL cell 
suspension was added to each well and sterile DPBS was 
added to the side empty area of plate around the wells to 
prevent excessive media evaporation. The plate was incubated 
at 37°C for four to five days until cells aggregated and formed 
compact spheroids. 
2.7 Staining and Imaging 
Cell viability was determined using fluorescent stains diluted 
in DMEM.  These were Nuc Blue (Life Technologies), 
calcein-AM and ethidium homodimer (Life Technologies) to 
stain for nuclei, living cells and dead cells, respectively. Cells 
were incubated with stains for 1 hour at 37°C in 5% (v/v) CO2 
in air. 
Vascular network formation was evaluated by 
immunostaining for CD31 with primary mouse anti-human 
CD31 (BD Biosciences) and secondary Cy3-conjugated 
donkey anti-mouse (Jackson Laboratories) antibodies, based 
on previously established  protocols.[9, 16] Bioprinted spheroids 
were also stained with mouse monoclonal [1C11] anti-human 
cardiac troponin T (Texas Red©) and mouse monoclonal [V9] 
to vimentin (Alexa 488) antibodies.  
Live imaging was performed using an EVOS AUTO FL 
fluorescent microscope system (Life Technologies) for phase 
and fluorescent imaging. Confocal imaging was performed 
using a Zeiss LSM 800 and a Leica Stellaris WL confocal 
imaging system. Images were processed using NIH Fiji 
software and Adobe Photoshop 2021 (Adobe Systems, In., 
San Jose, CA, USA). For 3D reconstructions, images were 
processed by Imaris v 9.2 (Bitplane, Concord, MA, USA). 
2.8 Functional Testing 
Physiological testing of contractile activity of bioprinted 
spheroids was carried out on the Myocyte Contractility 
System (IonOptix) including an AE31 Trinocular microscope 
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(Motic), MyoCam-S3, MyoPacer Field Stimulator and 
Fluorescence System Interface (FSI).  
Additional functional monitoring of spheroids was performed 
using CardioExcyte 96 (Nanion technologies GmbH, 
Germany) to record extracellular field potential (EFP) and 
impedance signals. Spheroids were directly bioprinted in the 
wells of the NSP-96 plate. Medium exchange was performed 
according to cell supplier recommendations. Impedance 
signals from spontaneously beating CSs were recorded with a 
sampling rate of 1 ms (1 kHz), and EFP data were collected at 
0.1 ms (10 kHz).  Data acquisition was controlled by 
CardioExcyte 96 Control software as described in [22]. 
2.9 Computational Modelling 
Surface Evolver was used for modelling spheroid fusion, in 
conjunction with ATOM TEXT EDITOR, which was used to 
edit code files. 
2.10 Statistical Analyses 
In order to measure the effects of VEGF on spheroid fusion, 
simple linear regression was performed using GraphPad 
Prism™ (La Jolla, CA). Experimental data from Brillouin 
microspectroscopy and pore size measurements are expressed 
as mean ± SEM (n > 4). ANOVA followed by Bonferroni post 
hoc test was performed using GraphPad Prism™ (La Jolla, 
CA). 
3. Results 
3.1 Optimal Hydrogel Composition 
An optimal hydrogel formulation was investigated by 
mixing alginate (Al) and gelatin (Ge) at different 
concentrations. These resulting hydrogels were tested for both 
printability and durability using a 300 μm diameter nozzle in 
either a customized extrusion REGEMAT3D or a 
commercially available BioX bioprinter (Figure S1). Cardiac 
spheroids (CSs) were mixed within Al/Ge hydrogels and then 
printed in rods (Figures 1 and S1). Hydrogels were 
subsequently polymerized by direct addition an ice-cold 
calcium chloride solution. This allowed optimal alginate 
crosslinking while preventing the gelatin from liquifying at 
higher temperatures. As they warmed up to 37°C in the 
incubator, 2%Al/6%Ge (w/v) hydrogels became liquid, 
resulting in spreading and lower accuracy of the print, as 
indicated by the asterisks in Figure 1. This type of hydrogel 
had low durability showing degradation as quickly as 3 days 
after printing (Figure 1). Increasing alginate and gelatin 
concentration in the hydrogel improved its durability and 
printability, with 4%Al/8%Ge (w/v) hydrogels showing 
optimal stability over 3 days in culture (Figure 1).  
Micromechanical properties of hydrogels with three 
different compositions of alginate and gelatin were evaluated 
using unconfined compression test and a Brillouin 
microspectroscopy technique. Since Brillouin 
microspectroscopy is label-free, non-contact and non-
destructive method, it was used to assess properties of the gels 
over all stages of fabrication and their stability over time. This 
method is based on the interaction of light waves with 
thermally excited acoustic phonons.[24] The Brillouin 
frequency shift (Ω) is directly related to the longitudinal 
storage modulus M∝Ω^2, which in turn, is inverse of the gel 
compressibility (β=1/M). Thus, Ω is indirectly related to the 
gel stiffness (lower compressibility corresponds to higher 
longitudinal modulus and higher stiffness). Figure 2 
compares the average frequency shift (Ω) across 12 
measurements for all gel compositions on the day of their 
fabrication, with the error bars indicating the standard 
deviation from the average value. All gels showed 
significantly higher frequency shift (Ω) compared to cell 
culture medium controls. However, 4%Al/8%Ge (w/v) 
hydrogels present the highest frequency shift throughout the 
two first stages of fabrication, i.e. before and after 
crosslinking. Incubation with culture media resulted in 
 
Figure 1. Durability Assessment of 3D Bioprinted 
Alginate/Gelatin (Al/Ge) Hydrogels in Culture 
Medium Over Three Days. Phase contrast microscopy 
images of bioprinted 2%Al/6%Ge, 3%Al/6%Ge and 
4%Al/8%Ge hydrogels immediately after CaCl2 
crosslinking (Days 0) and after three days (Day 3) in 
presence of culture medium in an incubator. Only 
bioprinted hydrogels containing 4%Al/8%Ge did not 
disintegrate after three days in culture, whereas 
2%Al/6%Ge and 3%Al/6%Ge dissolved in media at the 
same time. Dotted lines delimit area covered by intact 
hydrogels after being bioprinted, asterisks point at areas 
where the hydrogels dissolved between the dotted lines and 
arrowheads point at hydrogel leaving the rod. 
Magnification bars equal 2 mm. For a demonstration 
regarding the bioprinting process, please refer to Video 1. 
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hydrating and softening of the gels. All hydrogel formulations 
exhibited stiffening after the crosslinking stage and softening 
after incubation with medium, as expected based on 
poroelastic theory.[25] The latter, is most likely related to 
increases in gel hydration and partial gel swelling.[26] Our 
Brillouin microspectroscopy measurements over 14 days post 
fabrication of the 4%Al/8%Ge (w/v) hydrogels confirmed that 
presented optimal long-term stability, besides presenting the 
highest stiffness among the formulations tested (Figure S2). 
Our SEM analysis of bioprinted 4%Al/8%Ge (w/v) hydrogels 
confirmed the presence of pores for oxygen supply to cells 
within the construct (Figure S3). [23, 27, 28] 
 Additional measurements of hydrogels following their 
incubation with culture media using unconfined compression 
test confirmed that 4%Al/8%Ge (w/v) gel presents the highest 
stiffness compared to the other compositions (2%Al/6%Ge 
and 3%Al/6%Ge). In fact, the stiffest hydrogel has a Young’s 
modulus of 42.23±4.34 kPa (Figure S4). This value falls 
within the range of stiffness reported for animal and human 
cardiac tissues.[18, 29-31] 
3.2 Viability of Bioprinted Cardiac Spheroids in Al/Ge 
hydrogels 
Cardiac cells are very sensitive to oxygen and nutrient 
exchange, making them more susceptible to hypoxic condition 
in 3D cultures.[7] Therefore, cell viability in 3D bioprinted 
spheroids was evaluated in 4%Al/ 8%Ge hydrogels, which 
were optimal for long term cultures based on this and previous 
studies.[10] Calcein-AM and ethidium homodimer staining 
showed that cells in human bioprinted spheroids maintained 
high viability for at least 30 days, and did not statistically 
change compared to similar cultures at days 7 and 14 (Figure 
S5). It is interesting to note that while some cells seemed to 
grow out, the overall spheroidal structure was maintained even 
30 days after being bioprinted (Figure S5). Our evaluation of 
cardiac specific markers, such as cardiac troponin T and 
connexin 43, together with the expression of vimentin, a 
Figure 3. VEGF-mediated Angiogenesis in 3D 
Bioprinted Human Cardiac Spheroids within 
4%Al/8%Ge Hydrogels. (A) Z-stacks of the center of 
cardiac spheroids (CSs) treated with 50ng/ml VEGF over 
three days in culture and imaged using a confocal 
microscope (CD31 in red, Hoechst stain in blue). The 
CD31-positive endothelial cell network extends from the 
outer layer to the center of the VEGF-treated CS within 3 
days. (B) Collapsed Z-stacks taken with a confocal 
microscope of bioprinted CSs cultured for 7 days in the 
presence and absence of 50ng/ml VEGF. Arrowheads 
point to VEGF-induced angiogenic sprouts. CD31 (red) 
and Hoechst stain (blue). Magnification bars equal to 100 
(A) and 200 (B) µm. (C) 3D rendering analysis of the 
VEGF-treated CS shown in (B). Arrowheads point at 
CD31-positive endothelial cell network that extends from 
the bioprinted CS into the hydrogel. For complete 3D 
rendering analysis of the same VEGF-treated bioprinted 
CS, please refer to Video 2. 
Figure 2. Brillouin Microspectroscopy Measurements 
of Hydrogel Viscoelasticity. Statistical analysis of 
hydrogels’ Brillouin frequency shift measurements (GHz) 
[indirectly related to gel stiffness (i.e., the higher the shift 
- the stiffer the material)]. The 4%Al/8%Gel hydrogels is 
the stiffest hydrogel before and after crosslinking on Day 0 
of Figure 1. Incubation of hydrogels with culture medium 
resulted in softer gels and increased the variability of 
measurements in samples with increasing alginate 
concentrations. Brillouin frequency shifts for all hydrogel 
compositions are higher than that of the control culture 
medium only. (*p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001, n = 4). 
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marker of cardiac fibroblasts (Figure S6), confirmed the 
presence of the three cell types in bioprinted spheroids, in line 
with results from previous reports of cardiac spheroids in 
hanging drop culture.[16] 
3.3 VEGF-mediated Vascularization of Bioprinted Spheroids 
While improved vascularization remains one of the main 
challenges in cardiac tissue engineering, we have previously 
shown how vascular endothelial growth factor (VEGF), a 
well-known pro-angiogenic factor, is able to promote 
neovascularization of spheroids.[1, 7, 32] To promote new blood 
vessel formation, cardiac spheroids were treated with VEGF 
for up to 7 days. The VEGF treatment fostered vascularization 
as detected by CD31 immuno-staining of endothelial cells 
(Figure 3). Confocal microscopy analysis of bioprinted VCSs 
showed the growth of endothelial cells (ECs) from the outer 
cell layer towards the inner core of the CS (Figure 3A) and 
into the surrounding gel, with an increase by ~2.5 fold in 
CD31 staining (Figure 3B).   
3.4 Fusion of Bioprinted Vascularized Cardiac Spheroids in 
Alginate/Gelatin-based Hydrogels 
In order to evaluate the effects of VEGF on spheroid fusion, 
we measured the number of bioprinted CSs fusing over time. 
Figures 4 and S7 show how bioprinted spheroids from both 
control and VEGF groups undergo complete fusion over 4 
days. Bioprinted spheroids appear to shrink as they fuse, with 
the overall size of the fused spheroids in both groups 
becoming smaller than the combined size of the original 
spheroids. This optical observation, however, does not take 
into account the volume of the spheroids, which was not 
quantitatively evaluated in this study. It is important to 
 
Figure 4. VEGF Promotes Fusion of 3D Bioprinted CSs 
within 4%Al/8%Ge Hydrogels.  
(A) VEGF treatment of paired bioprinted CSs increased by 
more than 2-fold the number of completely fused spheroids 
after three days compared to bioprinted CSs fusing in 
control conditions (media only). (B) Phase contrast images 
of paired CSs fusing over three days (top panels) and 
collapsed Z-stacks of the fused CS (bottom panel) stained 
with anti-CD31 antibodies (red) and Hoechst stain (blue). 
Magnification bar equals 100 µm. For the 3D rendering 
analysis of the vascular network of the fused CS, please 
refer to Video 3. 
Figure 5. VEGF-promoted Fusion of Three Bioprinted 
Cardiac Spheroids within 4%Al/8%Ge Hydrogels. (A-
D) Phase contrast microscopy images of three bioprinted 
CSs fusing within 72h. (E) Collapsed z-stacks of the 72h 
fused CSs stained with antibodies against CD31 (red) and 
Hoeschst stain (blue). (F) Confocal z-stack taken from the 
center of the fused CS shown in (D) and (E). (G-H) Low 
(G) and high (H) resolution of the 3D rendering analysis 
of the 72h fused CSs. Arrowheads point at vascular 
network formed at the area of contact between fused CSs. 
Magnification bars equal 100 µm. See also Video 4 for 
animated spheroid fusion and Video 5 for 3D rendering 
analysis. 
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highlight that spheroid fusion occurs spontaneously in 
bioprinted CSs (Figure S8). 
The number of spheroids which underwent complete fusion 
(>75% fusion) was compared between control and VEGF-
treated groups. Spheroids from both groups presented 
complete fusion after 1 day as shown in Figure 4A. The 
application of VEGF increased efficiency of fusion by more 
than 2-fold over three days compared to the control group as 
shown in Figure 4B. 
Fusion of three CSs in bioprinted hydrogels generated a tissue 
construct where the fusion angle (120°) and directionality was 
maintained, as shown in Figure 5. Addition of VEGF to fusing 
CSs promoted vascular fusion detected by the CD31 staining 
in Figures 5 and S7. The hydrogel-controlled fusion was 
reconstructed using computer animation as shown in Video2. 
Confocal images taken in the center of the three fused CSs 
showed how the CD31 endothelium is organized in between 
the different CSs at the end of this process (Figure 5C). 
3.5 Functional Features of Bioprinted Cardiac Spheroid 
Cardiac spheroids bioprinted in 4% Al/ 8% Ge hydrogel 
contracted spontaneously and upon electrical stimulation. The 
spheroids demonstrated spontaneous beating frequencies in 
the physiological range of 0.3 and 1.2 Hz, corresponding to 
beating rates between 18 to 72 beats per minute (Figure 6 and 
Video 6). Contraction of CSs bioprinted in the CardioExcyte 
Plate induced gel movement as can be observed in Video 7. 
Bioprinted CSs also exhibited propagation of the electrical 
impulses, demonstrating interspheroid functional coupling as 
seen in Video 8. Figure 7 shows the extracellular field 
potential (EFP) and impedance signals recorded from 
spontaneously beating cardiac spheroids bio-printed in the 
CardioExcyte plate. The EFP reflects their electrical activity 
and the impedance amplitude represents an indirect measure 
of contractility.[22, 33] The recording demonstrates that the 
spheroid constructs exhibited robust synchronous electrical 
activity and contractile behavior sensitive to the compound 
treatment. Addition of isoproterenol (1 µM) shown in Figure 
7 resulted in the increased spontaneous beating rate induced 
by adrenergic stimulation.   
4. Discussion 
Modeling of physiological cardiac models remains one of the 
main challenges for optimal drug testing.[5, 34] Novel 3D 
culture systems, comprising 3D bioprinting of stem cell-
derived cardiac cells has provided promising results to move 
this research forward.[5, 34] Nevertheless, major challenges 
exist with respect to achieving optimal conditions for cell 
viability and function.[5, 34] In this study we have shown that 
bioprinted cardiac spheroids comprising human cardiac 
endothelial cells, fibroblasts and iPSC-derived 
cardiomyocytes represent the optimal microenvironment for 
cells to grow in for long term studies (Figures 1-2 and S1). 
This study has demonstrated how alginate/gelatin-based 
hydrogels with viscoelastic properties comparable to the ones 
of the native cardiac tissue allow optimal cell growth (Figure 
S5), tissue vascularization (Figure 3) and contractile function 
at physiological levels (Figure 6) and under pharmacological 
stimulation (Figure 7). Our study has demonstrated that the 
addition of gelatin to alginate hydrogels at 8% and 4% 
(respectively) generates optimal bioinks for cardiac cells to 
live and function properly, as previously indicated by 
others.[35] These soft hydrogels have a stiffness between 
18.28-42.23 kPa (Figure S4), which recapitulate the stiffness 
of human myocardium (approx. 50 kPa).[18, 29-31] This stiffness 
is tunable depending upon the concentration of alginate, as 
well as the concentration of the crosslinking solution. While 
in our study gelatin was added to promote cell adhesion within 
Figure 6. Field potential stimulation of a bioprinted CS. 
Field potential stimulation between 0.6 and 1.2 Hz was 
applied to record the contraction-relaxation function in 
bioprinted CSs using motion tracking (see also Video 6). 
Figure 7. Electrical Recording from Bioprinted CSs 
using the CardioExcyte96 plate. Phase contrast image of 
bioprinted CSs in proximity of the electrode at the center 
of a well in a CardioExcyte96 plate (left). Representative 
measurements of raw mean beat impedance and field 
potential waveforms shown before and after addition of 1 
µM isoproterenol to bioprinted CSs. Please refer to 
Videos 7 and 8 for live recording. 
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the hydrogel, it was not crosslinked (for instance, by addition 
of genipin), in order to allow cells to spontaneously populate 
the bioprinted hydrogels. No mass loss was detected in case of 
the hydrogel containing 4% (w/v) alginate and 8% (w/v) 
gelatin over 30 days. Our Brillouin microscopy measurements 
also confirmed that after crosslinking with calcium chloride, 
4%Al/8%Ge bioprinted hydrogels maintain their viscoelastic 
properties even after addition of culture media (Figure S2). 
The printability of the hydrogel was important to achieve 
accurate and consistent printing (Figure 1). Using lower 
concentrations of alginate was found to reduce viscosity of the 
non-crosslinked hydrogel, which increased spreading and 
reduced accuracy of the print. At the same time, the higher 
concentrations of gelatin partially reduced the viscosity of the 
hydrogel when heated, however, this also caused the gels to 
solidify faster by simply lowering the temperature below 26-
28 °C. It is important to note that as gelatin solidifies at room 
temperature, hydrogels containing higher gelatin 
concentrations tended to cause blockages in the print nozzles 
as these were not near the heating element of the bioprinter. In 
our study, 4%Al/8%Ge hydrogels were found to be optimal 
for their printability, durability and cardiac cell function. This 
is consistent with other studies showing that the presence of 
cells within a hydrogel changes its physical properties, such as 
viscosity.[36, 37] 
Generation of a vascular tree remains one of the main 
challenges for the biofabrication of bioengineered heart 
tissues using stem cell-derived cardiac cells, influencing cell 
survival and function.[1, 18] While advances in 3D bioprinting 
of cardiac tissues have been made over the recent years, these 
have not provided a comprehensive and controlled vascular 
network for optimal cardiac function.[38-41] Bioprinting of 
4%Al/8%Ge hydrogels containing CSs with high cell viability 
was facilitated  thanks to both their pre-vascularization and the 
presence of pores for oxygen supply (Figures S3 and S5). [23, 
27, 28] Cells showed no signs of damage from the printing, 
crosslinking or incubation process, as which is one of the main 
concerns with 3D bioprinting, specifically related to shear 
stress.[1] Pre-vascularized spheroids retained high viability 
with minimal numbers of dead cells over 30 days, which 
supports their potential use for long term in vitro studies to 
model and evaluate complex conditions, such as 
ischaemia/reperfusion injury and/or cardiac fibrosis.[17] 
VEGF is known for its pro-angiogenic activity in vivo and in 
vitro, and it has been previously employed to promote vascular 
network formation in spheroids.[32, 42] VEGF is well known to 
promote vasculogenesis and angiogenesis via proliferation 
and sprouting formation from endothelial cells early during 
development and in adult vessels.[43] Our study shows that 
VEGF promoted the formation of branch-like endothelial 
structures within the spheroid (Figure 3A) and from it into the 
surrounding hydrogel (Figure 3B-C and Video 2). These 
vascular-like networks may prevent cell death in the inner core 
of CSs even in absence of blood flow, which would normally 
become apoptotic for a diameter thicker than 100-200µm.[1, 7] 
The use of spheroids as building blocks and their fusion for 
tissue engineering has been previously explored.[13, 14] 
However, optimal cell viability and function in 3D bioprinted 
cardiac tissues using Al/Ge-hydrogels has not been previously 
demonstrated. Given their unique features, this presents the 
potential for regenerative medicine purposes to improve 
cardiac function following its transplantation.[19, 44] 
Previously, alignment of cardiac spheroids within hydrogels 
was established using other approaches. [45, 46] Other studies 
provided evidence that vascularized spheroids could be used 
to biofabricate complex tissues.[13, 14] This is the first study to 
provide a simulation of how 3D bioprinted cardiac spheroids 
can fused within Al/Ge hydrogels in order to be as be used as 
building blocks (Video 4). It also shows for the first time that 
VEGF not only promotes vascular network formation and 
tissue fusion in bioprinted hydrogels (Figure 3 and Video 2), 
but it also promotes CS fusion (Figure 4). The fused 
bioprinted CS following its treatment with VEGF allows the 
generation of a fully vascularized tissue (Figure 4 and Video 
3). Hydrogel-specific properties, such as viscoelastic 
properties comparable to the ones found in the native cardiac 
tissue and the presence of bioactive gelatin for optimal cell 
viability, provide mechanical cues to promote tissue fusion 
and induce vascular network formation. This is ideal for the 
engineering of novel in vitro cardiac models, together with 
potential applications for regenerative medicine on a larger 
scale.[14] Spheroid proximity is critical for optimal fusion in 
hydrogels, as previously demonstrated.[45, 46] In this study we 
evaluated the spontaneous CS fusion process occurring in 
presence or absence of VEGF. In this process, VEGF was able 
to promote fusion of bioprinted CSs at a faster rate compared 
with control bioprinted cultures. Other studies have focused 
on the controlled fusion by using other approaches.[45, 47] 
Further studies should evaluate the exact relationship between 
the initial distance between spheroids and optimal fusion in 
hydrogels with different characteristics. Our simulation of 
spheroid modeling highlighted how partial fusion for diverse 
geometrical shapes can be achieved based on hydrogel-
specific features (Figure 5 and Videos 4 and 5).  
As the use of in vitro bioprinted spheroids for pharmacological 
testing requires detectable contractile function, we evaluated 
how to detect it with two different methods developed by us. 
In our first approach, we used a Ionoptix system to measure 
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spontaneous contractile activity and under field potential 
(Figure 6 and Video 6). While we were not able to measure 
any contractile activity in 3D bioprinted single cells, our 
physiological testing using cardiac cells determined that 
4%Al/8%Ge hydrogels were permissive for intrinsic 
contractile function (Figure 6 and Video 6). Bioprinted 
spheroids displayed spontaneous contraction towards their 
center. However, these movements were very small and 
difficult to detect. The edges of the spheroid were largely 
unaffected by the intrinsic contraction and it was not possible 
to measure any contraction. However, these cardiac spheroids 
responded by synchronous contraction to electrical 
stimulation. This may be due to the close proximity of the cells 
in the spheroid allowing for intracellular communication and 
formation of electroconductive networks.[18] The presence of 
connexin 43 in bioprinted CS, together with cardiac troponin 
T (Figure S6), both cardiac specific markers and essential for 
optimal cardiac tissue conductivity and contractility was 
supporting the ability of the CS to contract as a whole tissue. 
Spheroids could be paced between 18 and 72 beats per minute 
(0.3 to 1.2Hz) spanning bradycardic and normal heart rate 
ranges in humans. This suggests that 3D bioprinted CSs have 
the potential to investigate long- and short-term effects of 
pharmaceuticals on the human heart, a much needed response 
to provide novel pathophysiological tools for cardiovascular 
drug discovery and toxicity.[5, 34] 
The EFP signal recording from spheroids showed that their 
electrical activity was sensitive to isoproterenol (Figure 7). 
However, the concomitant decrease in contractile signal 
indicated that bioprinted CSs still retain a negative force-
frequency relationship known for iPSC-derived 
cardiomyocytes. Electrical stimulation of iPSC-CMs has been 
shown to improve their maturation status and function[11] A 
similar approach could be applied to the CSs bioprinted in the 
new CardioExcyte plate with built-in electrical stimulation to 
improve their performance and utility for drug testing. 
Future studies aiming at improving the cardiac 
microenvironment in bioprinted CSs may focus on the 
recapitulation of pathophysiological conditions, such a heart 
attack in a Petri dish, in presence or absence of blood flow.[5] 
While there has been a lot of effort in engineering a more 
complex system, including the onset of organs-on-a-chip 
(including microfluidics devices), our study is the first one that 
directly demonstrates the spontaneous behavior of pre-
vascularized cardiac tissues in presence of developmentally 
relevant factors, such as VEGF. 
5. Conclusion 
We successfully 3D bioprinted viable and functional CSs in 
4%Al/8%Ge hydrogels, which present viscoelastic properties 
comparable to the ones of the native cardiac tissue. Overall, 
our study demonstrated that extrusion-based bioprinting of 
CSs in cardiac-tailored hydrogels represents a promising path 
forward in the engineering of in vitro models of human heart 
tissue. This has great potential for re-creating the human heart 
environment to study normal and pathological conditions in 
advanced cell-based models. A future direction for this 
research may include the use of patient-derived 
cardiomyocytes from iPSCs to create in vitro models for 
precision medicine. 
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